| Debra A. Glitz, M.d., P.l.l.c. | |
|
3290 W Big Beaver Rd Suite 509 Troy MI 48084-2903 | |
| (248) 290-2220 | |
| (248) 290-4019 |
| Full Name | Debra A. Glitz, M.d., P.l.l.c. |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 3290 W Big Beaver Rd, Troy, Michigan |
| Authorized Official Name and Position | Debra A Glitz (OWNER) |
| Authorized Official Contact | 2482902220 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Debra A. Glitz, M.d., P.l.l.c. 3290 W Big Beaver Rd Suite 509 Troy MI 48084-2903 Ph: (248) 290-2220 | Debra A. Glitz, M.d., P.l.l.c. 3290 W Big Beaver Rd Suite 509 Troy MI 48084-2903 Ph: (248) 290-2220 |
| NPI Number | 1225102775 |
|---|---|
| Provider Enumeration Date | 11/17/2006 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 8022052737 |
|---|---|
| Medicare Enrollment ID | O20050614000626 |
News Archive
A study describing how cells within blood vessel walls move en masse overturns an assumption common in the age of genomics - that the proteins driving cell behavior are doing so much multitasking that it would be near impossible to group them according to a few discrete functions.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.
EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health announced a new strategy to identify the total number of wildlife viruses that could potentially cause emerging disease outbreaks that threaten both public and wildlife health.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's Simponi will drive sales of the TNF-alpha inhibitor drug class to nearly triple by 2018 for the treatment of ulcerative colitis.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225102775 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 4301407088 (Michigan) | Primary |
| Provider Name | Debra A Glitz |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1326086059 PECOS PAC ID: 1759282221 Enrollment ID: I20050614000783 |
News Archive
A study describing how cells within blood vessel walls move en masse overturns an assumption common in the age of genomics - that the proteins driving cell behavior are doing so much multitasking that it would be near impossible to group them according to a few discrete functions.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.
EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health announced a new strategy to identify the total number of wildlife viruses that could potentially cause emerging disease outbreaks that threaten both public and wildlife health.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's Simponi will drive sales of the TNF-alpha inhibitor drug class to nearly triple by 2018 for the treatment of ulcerative colitis.
› Verified 9 days ago
News Archive
A study describing how cells within blood vessel walls move en masse overturns an assumption common in the age of genomics - that the proteins driving cell behavior are doing so much multitasking that it would be near impossible to group them according to a few discrete functions.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.
EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health announced a new strategy to identify the total number of wildlife viruses that could potentially cause emerging disease outbreaks that threaten both public and wildlife health.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's Simponi will drive sales of the TNF-alpha inhibitor drug class to nearly triple by 2018 for the treatment of ulcerative colitis.
› Verified 9 days ago
Hope Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 38815 Dequindre, Suite 103, Troy, MI 48083 Phone: 248-250-7343 Fax: 248-740-7772 | |
Perspectives Of Troy, P.c. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 888 W Big Beaver Rd Ste 1450, Troy, MI 48084 Phone: 248-322-0003 Fax: 248-244-1330 | |
Better Mental Health, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 W Big Beaver Rd, Suite 200, Troy, MI 48084 Phone: 248-703-6039 Fax: 248-680-6699 | |
Naomi Casement Lmsw, Caadc Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2265 Livernois Rd, Suite 260, Troy, MI 48083 Phone: 810-964-5400 Fax: 586-510-4800 | |
Diamond Cunseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 888 W Big Beaver Rd Ste 780, Troy, MI 48084 Phone: 586-217-3245 | |
Rich Blessings Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 W Big Beaver Rd Ste 1402, Troy, MI 48084 Phone: 248-561-3237 | |
Lillybrook Counseling Services Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 667 E Big Beaver Rd Ste 107, Troy, MI 48083 Phone: 248-250-6620 Fax: 248-250-6629 |